FIELD: medicine, pharmacy. SUBSTANCE: composition comprises the modified plasminogen activator of urokinase type mAPUT22 with specific activity 80 000-100 000 IU/mg of enzyme as an active substance that shows the definite amino acid sequence consisting of 403 amino acids and taken in the effective therapeutic dose and excipient also. Composition contains dextran with molecular mass 10 000-70 000 Da and sodium chloride as excipients. Composition can be used in ophthalmology. The novel composition shows the enhanced specific fibrinolytic and thrombolytic activity, it doesn't cause danger adverse effects in treatment of intraocular hemorrhages and fibrinous exudates arising in traumas and inflammatory diseases of eyes. EFFECT: enhanced effectiveness and valuable medicinal properties of composition. 5 cl
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR PREPARING HUMAN PLASMIN CONCENTRATE AND PRODUCT FOR ITS USING IN MEDICINE | 2004 |
|
RU2257224C1 |
METHOD OF TREATING ACUTE THROMBOSIS OF RETINA VEINS | 2010 |
|
RU2416402C1 |
PHARMACEUTICAL COMPOSITION POSSESSING FIBRINOLYTIC EFFECT | 2007 |
|
RU2323001C1 |
METHOD OF TREATMENT OF CLOTTAGE OF CENTRAL VIENNA OF RETINA | 2007 |
|
RU2352304C1 |
METHOD OF CONSERVATIVE TREATMENT OF RECURRENT HAEMOPHTHALMIA IN DIABETIC RETINOPATHY | 2012 |
|
RU2485944C1 |
METHOD OF TREATING CENTRAL SUBRETINAL HEMORRHAGES | 2010 |
|
RU2435553C1 |
PLASMINOGEN UROKINASE TYPE MODIFIED ACTIVATOR, DNA SEQUENCE, RECOMBINANT PLASMID, STRAIN-PRODUCER, METHOD FOR PREPARING PLASMINOGEN UROKINASE TYPE MODIFIED ACTIVATOR AND PHARMACEUTICAL COMPOSITION ELICITING THROMBOLYTIC EFFECT | 2001 |
|
RU2247777C2 |
METHOD FOR THROMBOSIS TREATMENT IN CENTRAL VEIN OF RETINA AND ITS BRANCHES | 2007 |
|
RU2337656C1 |
METHOD FOR APPLYING ENZYMOTHERAPY | 2006 |
|
RU2303457C1 |
METHOD OF TREATING RETINAL AND VITREOUS HEMORRHAGE | 2013 |
|
RU2513473C1 |
Authors
Dates
2003-11-20—Published
2002-11-14—Filed